menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading  T cells and deployable for TCR-T and CAR-T cell therapy Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of
Read More

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass. , April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and
Read More

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia

NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia CAMBRIDGE, Mass. , March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Decision Relating to CRISPR/Cas9 Genome Editing Technology in Eukaryotic Cells

Background In May 2012, the Regents of University of California, University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”) filed a patent application for their CRISPR/Cas9 genome editing technology. The CVC team led by Drs. Jennifer Doudna and Emmanuelle Charpentier promptly brought
Read More

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform    NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen frequently found in acute myeloid leukemia (AML) and other hematologic and
Read More

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated
Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress

On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy on February 28 , at 4:30 p.m. ET Plans to present interim data from ongoing first-in-human study of NTLA-2002 for hereditary
Read More

Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies

State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies New facility in Waltham, Massachusetts expected to be operational in 2024 CAMBRIDGE, Mass. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

Fourth quarter and full-year 2021 financial results – February 24 , at 8:00 a.m. ET Updated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis – February 28 , at 4:30 p.m. ET CAMBRIDGE, Mass. , Feb.
Read More

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer

Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic
Read More
RSS FEEDS
PRINT PAGE